Accelerating sales growth
"Glycorex had a strong second quarter of 2022 with solid double-digit growth. Demand grew as the effects of the COVID-19-pandemic continued to subside which, combined with an effective implementation of the company's G4G strategy, delivered a very good quarter." -
Financial information
April -
- Net sales:
SEK 11.2 million (8.0) -
Operating income:
SEK -1.7 million (-2.2) -
Net income for the period:
SEK -1.7 million (-2.3) -
Earnings per share:
SEK -0.02 (-0.03)
Events in the second quarter
- Distributor agreement in
Chile . Initiated marketing efforts. -
Registration of Glycosorb® ABO in
South Africa . First order for Glycosorb® ABO from distributor. -
New transplant centers added in
England andIndia . -
Participation as an exhibitor at the ATC (
American Transplant Congress ) inBoston . - Indian customer reports successful blood group incompatible liver transplantation from a living donor using Glycosorb® ABO.
-
Order of Glycosorb® ABO from reputable centers in
England for the treatment of Pure Red Cell Aplasia after a blood group incompatible bone marrow transplant. - Meetings with potential Glycosorb® UBP key customers in key European markets.
- Delivery of the Glycosorb® UBP to two European reference centers for evaluation.
- Positive initial results obtained for the reduction of anti-A/B antibodies on platelet concentrate.
- Announcement of partner in the Rheumatoid Arthritis project.
Significant events after the balance sheet date
- The CEO of
Glycorex Transplantation AB (publ) resigns his employment.
THE ENTIRE INTERIM REPORT FOR QUARTER 2 2022 IS ATTACHED
For further information, please contact:
Scheelevägen 27
SE-223 63
Phone: +46 46 286 5230
info@glycorex.com
glycorex.com
This information is such information that
Brief information about the company
Glycosorb® ABO is one of
The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.
https://news.cision.com/glycorex-transplantation/r/glycorex-transplantation-ab--gtab-b--interim-report-january-june-2022,c3620631
https://mb.cision.com/Main/15286/3620631/1619215.pdf
(c) 2022 Cision. All rights reserved., source